Every material Form 8-K Equillium, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Equillium said on October 26, 2026 that it dosed the first subject in its Phase 1 trial of EQ504 in Australia, which triggered the Milestone Closing of its August 2025 private placement. The company sold 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669 for gross proceeds of about $20.0 million before fees. The sale adds to the share count, and the company must file resale registration statements within 30 days, with cash penalties for registration failures.
Milestone Closing on October 26, 2026: 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669 each.
Gross proceeds of about $20.0 million before fees; total equity private placement proceeds of about $50 million.
Investors waived the $2.50 weighted average price threshold on October 26, 2026.
Registration statements for resale must be filed within 30 days of the Milestone Closing, with cash penalties for registration failures.
Equillium said it received ethics committee approval and clearance from Australia's Therapeutic Goods Administration under the Clinical Trial Notification scheme for a Phase 1 trial of EQ504. The company expects to begin dosing healthy participants by early November 2026, moving the drug candidate closer to clinical data.
Approvals: Human Research Ethics Committee approval and TGA clearance in Australia for the EQ504 Phase 1 trial
Timing: Company expects to begin dosing healthy participants by early November 2026
Design: Randomized, double-blinded, placebo-controlled, single-center study with three parts, including a 10-day multiple ascending dose portion and a food effect cohort
Equillium reported a second-quarter 2026 net loss of $4.7 million, or $(0.04) per share, compared with $5.7 million, or $(0.16) per share, a year earlier. The company said its $57.2 million in cash is expected to fund planned operations into 2029, and it reiterated that a Phase 1 study of EQ504 is expected to begin in the fourth quarter of 2026.
Net loss for Q2 2026 was $4.7 million, or $(0.04) per basic and diluted share, versus $5.7 million, or $(0.16) per share, in Q2 2025.
R&D expenses were $2.8 million, down from $4.1 million a year earlier; G&A expenses were $2.4 million, up from $2.1 million.
Cash and cash equivalents were $57.2 million as of June 30, 2026, down from $61.3 million as of March 31, 2026.
Weighted-average shares outstanding were 111,805,635 in Q2 2026, compared with 35,719,317 in Q2 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Equillium, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →